Circulating individual inflammatory markersa
|
G1–10 | Inflammatory mediators |
G1 | Cytokines |
| 1–42 | Interleukins | 94–96 | Interferons |
| 43–47 | Colony-stimulating factors | 97–99 | Tumour necrosis factor |
| 48–51 | Adipokines | 100 | Macrophage migration inhibitory factor |
| 52–93 | Chemokines | | |
G2 | Growth factors |
| 101 | Transforming growth factor | 112 | Hepatocyte growth factor |
| 102–104 | Vascular endothelial growth factor | 113 | Nerve growth factor |
| 105 | Platelet-derived growth factor | 114,115 | Insulin, insulin-like growth factor |
| 106–108 | Fibroblast growth factor | 116–118 | Endothelins |
| 109,110 | Epidermal growth factor | 119,120 | Renin-angiotensin system |
| 111 | Placental growth factor | 121–129 | Angiopoietin, angiopoietin-like protein |
G3 | Transcription factors |
| 130 | Nuclear factor kappa B | 133–138 | Signal transducers and activators of transcription |
| 131,132 | Nuclear factor erythroid 2-related factor | 139–141 | Hypoxia-inducible factor |
G4 | Immunoglobulins |
| 142–149 | Cell-adhesion molecules | 150–152 | Programmed cell death protein |
G5 | Eicosanoids |
| 153,154 | Cyclooxygenase | 160 | Lipoxygenase |
| 155–158 | Prostaglandins | 161–164 | Leukotrienes |
| 159 | Thromboxane | 165 | Lipoxins |
G6 | Acute phase proteins |
| 166–168 | C-reactive protein | 188–195 | Plasminogen activation system |
| 169–172 | Pentraxins family | 196–197 | Microglobulins |
| 173–175 | Serum amyloid A | 198–201 | Transport proteins |
| 176–178 | Alpha globulins | 202–205 | Complement system |
| 179–184 | Extracellular matrix proteins | 206–209 | Albumin, transferrin |
| 185–187 | Fibrinogen, D-dimer | | |
G7 | Matrix metalloproteinases |
| 210–225 | Matrix metalloproteinases | | |
G8 | Redox active mediators |
| 226,227 | Metalloproteins (haemoglobin; heme) | 233 | Calcitriol |
| 228–231 | Vitamin D (25-hydroxyvitamin D) | 234 | Melatonin |
| 232 | Calcidiol | 235 | 6-sulfatoxymelatonin |
G9 | Lipoproteins |
| 236–238 | Very low-, low-, high-density lipoprotein | 241 | Total cholesterol |
| 239 | Oxidised low-density lipoprotein | 242 | Triglycerides |
| 240 | Apolipoprotein | | |
G10 | Adrenal cortex hormones and neurotransmitters |
| 243–245 | Glucocorticoids | 251–253 | Catecholamines |
| 246–250 | Neurotransmitters | | |
G11–13 | Inflammatory effector cells |
| 254 | Platelets | 259–265 | White blood cells |
| 255–258 | Red blood cells | | |
Combining multiple inflammatory markers (into a score)a
|
cG11.13 | White blood cells-platelets parameters |
| 266 | Lymphocyte to monocyte ratio | 269 | Derived Neutrophil to lymphocyte ratio |
| 267 | Neutrophil to lymphocyte ratio | 270–272 | Novel combined scoring systemb
|
| 268 | Platelet to lymphocyte ratio | | |
cG6 | Acute phase proteins parameters, combinations |
| 273–275 | Glasgow prognostic scores | 277–280 | Novel combined scoring systemb
|
| 276 | Prognostic inflammatory and nutritional index | | |
cG11.6 | White blood cells-acute phase proteins parameters, combinations |
| 281–285 | Novel combined scoring systemb
| | |
cG11.6.8 | White blood cells-acute phase proteins-redox active mediators parameters |
| 286 | Combined haemoglobin, albumin, lymphocyte, platelet | | |
cG10 | Lipoprotein particle-derived measure of insulin resistance |
| 287 | Lipoprotein insulin resistance score | | |